Can I read Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia on EtoBox?

Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia by Wolfgang Kern; Claudia Schoch; Torsten Haferlach; Susanne Schnittger is a Medicine article available to read on EtoBox.

What is Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia about?

Monitoring minimal residual disease (MRD) becomes increasingly important in the risk-adapted management of patients with acute myeloid leukemia (AML). The two most sensitive and quantitative methods for MRD detection are multiparameter flow cytometry (MFC) and real-time polymerase chain reaction (QRT-PCR). Fusion gene-specific PCR in AML is based on the RNA level, and thus in contrast to MFC expression levels rather than cell counts are assessed. For both methods independent prognostic values have been shown. The strong power of MFC has been shown mainly in the assessment of early clearance of the malignant clone. MRD levels in AML with fusion genes have the strongest prognostic power after the end of consolidation therapy. In addition, with QRT-PCR highly predictive initial expression levels can be assessed. With both methods early detection of relapse is possible. So far, validated PCR-based MRD was done with fusion genes that are detectable in only 20-25% of all AML MFC is superior since it is applicable for most AML. However, QRT-PCR is still more sensitive in most cases. Thus, it is desirable to establish new molecular markers for PCR-based studies. Large clinical trials will

Who reads Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia?

Author

Wolfgang Kern; Claudia Schoch; Torsten Haferlach; Susanne Schnittger

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 1040-8428)

Published

2005

Language

EN

Field

Medicine (Health Sciences)